Respiratory Medicine
Volume 104, Issue 10 , Pages 1482-1489 , October 2010

Sustained 24-h efficacy of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients

  • C. Verkindre

      Affiliations

    • Hopital de Bethune, Beuvry, France
    • Corresponding Author InformationCorresponding author. Tel.: +33 32 164 4139; fax: +33 32 164 6350.
    • ,
  • Y. Fukuchi

      Affiliations

    • Juntendo University, Tokyo, Japan
    • ,
  • A. Flémale

      Affiliations

    • Chirec – Parc Léopold, Service de Pneumologie, Bruxelles, Belgium
    • ,
  • A. Takeda

      Affiliations

    • Dohoku National Hospital, Hokkaido, Japan
    • ,
  • T. Overend

      Affiliations

    • Novartis Horsham Research Centre, West Sussex, UK
    • ,
  • N. Prasad

      Affiliations

    • Novartis Horsham Research Centre, West Sussex, UK
    • ,
  • M. Dolker

      Affiliations

    • Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

Received 7 December 2009 ,Accepted 9 April 2010.

References 

  1. Global Initiative for Chronic Obstructive Lung Disease (GOLD) . Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. www.goldcopd.com2008;
  2. Viegi G, Pistelli F, Sherrill DL, et al. Definition, epidemiology and natural history of COPD. Eur Respir J. 2007;30:993–1013
  3. Taylor T, Kotch A, Rice K, et al. Ipratropium bromide hydrofluoroalkane inhalation aerosol is safe and effective in patients with COPD. Chest. 2001;120:1253–1261
  4. Cuvelier A, Muir JF, Benhamou D, et al. Dry powder ipratropium bromide is as safe and effective as metered-dose inhaler formulation: a cumulative dose-response study in chronic obstructive pulmonary disease patients. Respir Care. 2002;47:159–166
  5. Van Noord JA, Bantje TA, Eland ME, et al. A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. The Dutch Tiotropium Study Group. Thorax. 2000;55:289–294
  6. Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J. 2002;19:217–224
  7. Haddad E-B, Patel H, Keeling JE, et al. Pharmacological characterization of the muscarinic receptor antagonist, glycopyrrolate, in human and guinea-pig airways. Br J Pharmacol. 1999;127:413–420
  8. Singh D, Corris PA, Tansley R. NVA237, a once-daily inhaled anticholinergic, provides 24-hour bronchodilator efficacy in patients with moderate-to-severe COPD. Eur Respir J. 2006;28(Suppl. 50):3051
  9. Kuna P, Vinkler I, Overend T, et al. Efficacy and tolerability of NVA237, a once daily long-acting muscarinic antagonist, in COPD patients. Eur Respir J. 2007;30(Suppl. 51):2135
  10. Global Initiative for Chronic Obstructive Lung Disease (GOLD) . Executive summary (2006 revision): global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. www.goldcopd.com
  11. Quanjer PH, Tammeling GJ, Cotes JE, et al. Lung volumes and forced ventilatory flows: report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal: official statement of the European Respiratory Society. Eur Respir J. 1993;16:5–40
  12. The Japanese Respiratory Society . Guidelines for the diagnosis and treatment of COPD. pocket guide www.jrs.or.jp
  13. John A, Quenouille M. Experiments: design and analysis. 2nd ed.. Riverside, New Jersey, USA.: Hafner Press; 1977;
  14. Cazzola M, MacNee W, Martinez F, et al. ATS/ERS Task Force Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J. 2008;31:416–468
  15. Vogelmeier C, Verkindre C, Cheung D, et al. Safety and tolerability of NVA237, a once-daily long-acting muscarinic antagonist, in patients with COPD. Eur Respir J. 2008;32(Suppl. 52):476s

PII: S0954-6111(10)00159-9

doi: 10.1016/j.rmed.2010.04.006

Respiratory Medicine
Volume 104, Issue 10 , Pages 1482-1489 , October 2010

Article Tools

* Image Usage & Resolution